烟台论坛-烟台社区

 找回密码
 点这里注册

QQ登录

只需一步,快速开始

扫一扫,访问移动社区

查看: 6963|回复: 10
打印 上一主题 下一主题
收起左侧

辉瑞的官方回应,自己看吧~

[复制链接]
     
跳转到指定楼层
楼主
发表于 2023-1-29 15:35 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式 | 来自山东

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有帐号?点这里注册

x
Science
Products
2Pfizer
Pfizer Responds to Research Claims
Stories
Newsroom
About
Q
Contact Us
Friday, January 27, 2023 -08:00pm
New York, N.Y., January 27, 2023 - Allegations have recently been made related to gain of function and directed evolution
research at Pfizer and the company would like to set the record straight.
In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a
vaccine update is required.
In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID~", Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID'S two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease-a non-infectious part of the virus.In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus. It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.
Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer
remains committed to transparency and helping alleviate the devastating burden of this disease.


自己看吧~反正是大体意思就是没否认在研究,但研究是为了更好的开发药物~
     
沙发
 楼主| 发表于 2023-1-30 16:00 | 只看该作者 | 来自山东
研究是研究了,但是为啥研究的就不好说了~
回复

使用道具 举报

     
板凳
发表于 2023-1-30 16:06 | 只看该作者 | 来自山东
twitter上这个视频已经删的干干净净,只有一些铁杆*华还揪着里面一句话,大肆宣传病毒是武汉制造的
回复

使用道具 举报

     
地板
 楼主| 发表于 2023-1-30 16:08 | 只看该作者 | 来自山东
SE图哥 发表于 2023-1-30 16:06
twitter上这个视频已经删的干干净净,只有一些铁杆*华还揪着里面一句话,大肆宣传病毒是武汉制造的

十有八九都是小润人和小殖人~
回复

使用道具 举报

     
5
发表于 2023-1-30 16:20 | 只看该作者 | 来自山东
生化危机里面的那个什么保护伞公司??哈哈哈
回复

使用道具 举报

头像被屏蔽
     
6
发表于 2023-1-30 16:53 | 只看该作者 | 来自山东
提示: 作者被禁止或删除 内容自动屏蔽
回复

使用道具 举报

     
7
发表于 2023-1-30 17:46 | 只看该作者 | 来自山东
大体意思是辉瑞承认的确在实验室制造变异毒株,但目的是为了研究药物而已,辉瑞需要确定病毒对paxlovid的潜在耐药突变,并强调这符合美国监管机构的要求。
回复

使用道具 举报

     
8
发表于 2023-1-30 19:12 | 只看该作者 | 来自陕西
csasd 发表于 2023-1-30 17:46
大体意思是辉瑞承认的确在实验室制造变异毒株,但目的是为了研究药物而已,辉瑞需要确定病毒对paxlovid的潜 ...

没看出来那句话说的制造变异毒株,请标示出来。
回复

使用道具 举报

9
发表于 2023-1-30 19:19 烟台论坛手机版 | 只看该作者 | 来自山东
论坛英语过硬的
给美丽国洗地的
为辉瑞开脱的进来说说
回复

使用道具 举报

头像被屏蔽
10
发表于 2023-1-30 19:21 烟台论坛手机版 | 只看该作者 | 来自山东
提示: 作者被禁止或删除 内容自动屏蔽
回复

使用道具 举报

     
11
 楼主| 发表于 2023-1-31 10:48 | 只看该作者 | 来自山东
gudiehu 发表于 2023-1-30 19:12
没看出来那句话说的制造变异毒株,请标示出来。

In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus.  

这个说制造不太对,算是寻找吧~
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 点这里注册

本版积分规则

社区地图 | 删帖帮助 | 手机版

烟台论坛-烟台社区 鲁ICP备05034347号 鲁公网安备 37060202000105号

免责声明:本网页提供的文字图片及视频等信息都由网友产生,本网站仅提供存储服务,如有侵犯您的知识产权,请及时与我们联系,我们将第一时间处理。

快速回复 返回顶部 返回列表